Plus, get the best of BroadwayWorld delivered to your inbox, and unlimited access to our editorial content across the globe. From headlining iconic venues in New York and Los Angeles, to gracing the ...

Sanofi has announced that Lyxumia® (lixisenatide), a once-daily GLP-1 receptor agonist under development for type 2 diabetes, achieved its primary efficacy endpoint of significant HbA1c reduction vs.

Forbes contributors publish independent expert analyses and insights. Scott Hutcheson teaches leadership at Purdue University. In the fast-moving, disruption-heavy environment most of us are currently ...

It can be frustrating to measure the progress of personal growth that is a result of talk therapy. This change is often slow and incremental, and we want results now. Especially after we’ve spent a ...

In February The Scientist ran a timely article by Eugene Russo discussing the new and exciting advances in the regulation and targeting of genes for gene therapy procedures.1 The elegant studies from ...

The idea is gathering momentum and is shaping up to be one of the big Budget stories. It’s controversial and would enrage older voters if Chancellor Rachel Reeves presses ahead. The Treasury won’t ...